Ambrx Biopharma Total Assets 2020-2022 | AMAM

Ambrx Biopharma total assets from 2020 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Ambrx Biopharma Annual Total Assets
(Millions of US $)
2021 $229
2020 $134
2019 $62
Ambrx Biopharma Quarterly Total Assets
(Millions of US $)
2021-12-31 $229
2021-06-30 $214
2020-12-31 $134
2019-12-31 $62
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00